

Do not miss this opportunity to learn more about **new and emerging treatment options in MS** from leading experts in the field



PRESENTER (USA PERSPECTIVE)

Jeffrey A. Cohen, MD
Hazel Prior Hostetler Professor of Neurology
Cleveland Clinic Lerner College of Medicine
Director, Experimental Therapeutics
Mellen Center for MS Treatment and Research
Cleveland Clinic, Cleveland, OH USA



MODERATOR (CDN PERSPECTIVE)

**Mark Freedman, HBSc, MSc,
MD, CSPQ, FAAN, FRCPC**
Professor of Medicine, Neurology,
University of Ottawa
Director, Multiple Sclerosis Research Unit
Ottawa Hospital

JOIN US

in a LIVE virtual session to discuss
how **new sphingosine 1-phosphate
receptor modulators** fit into the
course of MS treatment

LEARNING OBJECTIVES

Upon completion of this educational activity,
you will be better able to:

- ⦿ Recognize the current therapeutic landscape and unmet needs in multiple sclerosis (MS)
- ⦿ Describe the mechanism of action of novel therapies targeting sphingosine 1-phosphate (S1P) receptors
- ⦿ Discuss recent clinical trial data of S1P receptor modulators for the treatment of patients with MS
- ⦿ Identify where these agents fit into the treatment landscape

**EARN MOC
SECTION 3
CREDITS!**

DATE

Wednesday, October 14

TIME

7:00-8:00 PM ET

LOCATION

Virtual event
(link to be provided upon registration)

**Please reserve
your spot **today**
by registering at:**

www.msspeakertour.ca

MS, Multiple sclerosis; MOC, Maintenance of Certification

This program is an accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Neurological Sciences Federation for 3.0 credits per hour up to a maximum of 6 credits. This program was co-developed by the Canadian Neurological Sciences Federation and Hc³ Communications, and was planned to achieve scientific integrity, objectivity and balance. The Program was supported by Bristol Myers Squibb Canada Co. who provided an unrestricted education grant and in-kind support.